Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Alpha Tau Medical Ltd ( (DRTS) ) is now available.
On January 5, 2026, Alpha Tau Medical announced it has submitted the first module of its pre-market approval application to the U.S. Food and Drug Administration for Alpha DaRT in the treatment of recurrent cutaneous squamous cell carcinoma in patients who are not candidates for surgery or standard radiation and lack curative systemic options. The FDA has allowed the company to use a modular PMA approach, enabling staged review of non-clinical and other data, and the initial module focuses on comprehensive non-clinical documentation; this step, taken in parallel with the ongoing multi-center ReSTART pivotal study that is expected to complete patient recruitment in the first quarter of 2026, marks a key regulatory milestone that could help streamline U.S. review and potentially strengthen Alpha Tau’s position in the skin cancer treatment market if future modules and clinical results support approval.
The most recent analyst rating on (DRTS) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn), which increases reliance on external funding despite improved balance-sheet solvency. Technicals are a meaningful offset with a strong uptrend and positive momentum, while valuation is not supportive given the negative P/E and lack of dividend yield.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Founded in 2016 and based in Israel, Alpha Tau Medical Ltd. is an oncology therapeutics company focused on the research, development and potential commercialization of Alpha DaRT, an alpha-radiation-based therapy for solid tumors. The technology, originating from Tel Aviv University, is designed to deliver highly potent, localized alpha irradiation via intratumoral radium-224 sources that aim to destroy tumors while sparing surrounding healthy tissue.
Average Trading Volume: 135,859
Technical Sentiment Signal: Buy
Current Market Cap: $411.8M
Learn more about DRTS stock on TipRanks’ Stock Analysis page.